RESEARCH Open Access

Investigation of the relationship between community-acquired respiratory distress syndrome toxin and the high-mobility group box protein 1-toll-like receptors-myeloid differentiation factor 88 signaling pathway in *Mycoplasma pneumoniae* pneumonia

Yujie Fan[†], Ying Ding[†], Yuqin Li, Dandan Zhang, Min Yu, Wei-fang Zhou^{*} and Xiaoxing Kong^{*}

Abstract

Background: In recent years, reports of refractory *Mycoplasma pneumoniae* pneumonia (RMPP) have gradually increased, including reports on how these conditions threaten the lives of children. However, the specific mechanism of *Mycoplasma pneumoniae* pneumonia (MPP) remains unclear. This study aimed to investigate the relationship between community-acquired respiratory distress syndrome toxin (CARDSTX) and High-mobility group box protein 1-Toll-like receptors-Myeloid differentiation factor 88 (HMGB1-TLRs-MyD88) in MPP and to examine the immune pathogenesis of *Mycoplasma pneumoniae* infection.

Methods: Children who were diagnosed with MPP and examined by bronchoscopy were included in the MPP group. Additionally, children who underwent bronchoscopy because of bronchial foreign bodies in the same period were included in the control group. Gene expression of CARDS TX, HMGB1, Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4), MyD88, and cluster of differentiation 14 (CD14) in bronchoalveolar lavage fluid (BALF) were detected using real-time reverse transcription-polymerase chain reaction. Correlations between CARDS TX and HMGB1-TLRs-MyD88 were analyzed.

Results: CARDS TX, HMGB1, TLR2, MyD88, and CD14 mRNA expression in BALF in the MPP group was significantly higher than that in the control group (all P < 0.05). CARDS TX mRNA expression was positively correlated with HMGB1, TLR2, MyD88, and CD14 mRNA expression (all P < 0.05). Furthermore, HMGB1 mRNA expression was positively correlated with TLR2, MyD88, and CD14 mRNA expression (all P < 0.05).

Conclusions: CARDS TX may participate in the immune pathogenesis of MPP through the HMGB1-TLRs/CD14-MyD88 pathway.

Keywords: *Mycoplasma pneumoniae* pneumonia, Community-acquired respiratory distress syndrome toxin, Highmobility group box protein 1, Toll-like receptor 2, Cluster of differentiation 14

*Correspondence: zwf_1969@163.com; kongxiaoxingshi@sina.com [†]Yujie Fan and Ying Ding contributed equally to this work. Department of Infectious Disease, Children's Hospital of Soochow University, Soochow University, Suzhou 215003, China



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Fan et al. Italian Journal of Pediatrics (2022) 48:64 Page 2 of 6

Background

Community-acquired pneumonia is one of the main diseases in hospitalization of children worldwide, especially in developing countries. Among children older than 5 years, community-acquired pneumonia is caused by *Mycoplasma pneumoniae* (MP) infection in 40% of children [1]. In recent years, the number of cases of refractory *Mycoplasma pneumoniae* pneumonia (RMPP) has significantly increased [2]. Some studies have shown that community-acquired respiratory distress syndrome toxin (CARDS TX) is an important toxin produced by MP [3]. High-mobility group box protein 1 (HMGB1) is highly expressed in RMPP, suggesting that it may play an important role in the pathogenesis of MP [4].

In this study, we aimed to detect the relative gene expression of CARDS TX, HMGB1, and their related receptors in bronchoalveolar lavage fluid (BALF) of children with MPP. We also aimed to examine the relationships between CARDS TX and HMGB1, Toll-like receptors (TLRs), and myeloid differentiation factor 88 (MyD88), and to further explore the pathogenic mechanism of MP.

Methods

Patients

From January 2018 to June 2019, 66 children were diagnosed with MPP and examined by bronchoscopy in the affiliated Children's Hospital of Suzhou University. These children were included in the MPP case group (mean \pm SD age, 5.58 ± 2.67 years; 32 boys, 34 girls). A total of 20 children who underwent bronchoscopy because of bronchial foreign bodies in the same period were included in the control group (mean \pm SD age, 5.23 ± 2.24 years; 12 boys, 8 girls).

MPP was diagnosed according to the following: (1) the diagnostic criteria of community-acquired pneumonia in children were met [5]; (2) compatible with bronchoscopy indications [6]: children requiring bronchoscopy and alveolar lavage with no significant improvement in clinical symptoms, signs and/or reexamination of imaging after 5 to 7 days of outpatient or in-patient treatment; and (3) MP DNA > 1.0×10^3 copies was detected in BALF.

Children were included in the control group if they met the following criteria: (1) there was a clear history of foreign body inhalation and irritant cough, and the course of disease was shorter than 7 days; (2) an imaging examination showed a clear shadow of foreign bodies, but did not indicate inflammatory changes; and (3) there was no history of pulmonary infection within 2 months.

The exclusion criteria for the study were as follows. Other viral and bacterial infections were excluded. Additionally, patients with an incomplete history and data of bronchopulmonary dysplasia, pulmonary mass, genetic

and metabolic diseases, hematological diseases, and immunodeficiency were excluded.

The study was approved by the hospital ethics committee and informed consent was obtained from the parents of the children.

Collection of BALF in children with pneumonia

All children fasted before the operation and did not drink any water. The children were placed in the supine position and underwent bronchoscopy and bronchoalveolar lavage after local anesthesia. According to the results of an imaging examination, the healthy side was examined first to determine whether there were inflammation and abnormalities. The lesion site was then examined and lavage was performed with normal saline at 37 °C (each injection was 5–10 ml of lavage, and the total amount was $\leq 5-10$ ml/kg). The lavage fluid was then sucked out through negative pressure, and the reabsorption rate of each lavage fluid was $\geq 40\%$. The obtained BALF was stored in a sterilized collector for later inspection.

Real-time PCR for detection of MP

A real-time polymerase chain reaction (PCR) procedure (Daan Gene Co. Ltd., Guangzhou, China), which was approved by the State Food and Drug Administration of China, was used to detect MP in real time [7]. Briefly, the sample of BALF was shaken, centrifuged, and then removed liquid supernatant. The sediment was collected, blended with 50 µL of DNA extraction solution, incubated at 100 °C for 10 min, and centrifuged at 12,000 rpm for 5 min. PCR amplification was performed using primers and probes (Daan Gene Co. Ltd.) in a 7600 real-time PCR system (Applied Biosystems, Foster City, CA, USA). The PCR conditions were as follows: 93 °C for 2 min; 10 cycles of 93 °C for 45 s, and 55 °C for 60 s; and 30 cycles of 93 °C for 30 s and 55 °C for 45 s. Quantitative curves were drawn with standard control samples at several concentrations.

Detection of CARDS TX, HMGB1, receptor for advanced glycation end products, TLR2, TLR4, MyD88, TLR6, and CD14 mRNA expression

BALF samples were centrifuged at $15,000 \times g$ at 4 °C for 5 min, and 0.5 ml of Trizol (Aidlab Biotechnologies Co., Ltd., Beijing, China) was added to the bottom of the tube for precipitation. Total RNA was extracted and reverse transcribed to synthesize cDNA. The mRNA expression of CARDS TX, HMGB1, receptor for advanced glycation end products (RAGE), TLR2, TLR4, MyD88, TLR6, and CD14 was determined using real-time PCR. CARDS TX used pdhA as the internal reference, and the others used 18 s as the internal reference. Gene expression was assessed using the comparative cycle threshold (Ct)

Fan et al. Italian Journal of Pediatrics (2022) 48:64 Page 3 of 6

Table 1 Forward and reverse primers used for real-time PCR

DNA	F(5'→3')	R (5' \rightarrow 3') CTTCGTGCATTGCTTCGTAACTCGC	
pdh A	ACTGGTTCTGCCCTACCTTCCGTTCC		
18 s	ACGACCCATTCGAACGTCTG	CCGTTTCTCAGGCTCCCTC	
CARDSTX	TTCCACTTCAGAAACACCCACAGC	TCAATCAGGGCACGCAAACG	
HMGB1	TGTAAGGCTGTGTAAGATT	AAGGTTAGTGGCTATTGAA	
RAGE	GTGAAGGAACAGACCAGGAGAACA	TGGGCTGAAGCTACAGGAGAA	
TLR2	TGAGGAACTTGAGATTGAT CACGGAACTTGTAACATC		
TLR4	TCAGTGTGCTTGTAGTAT CCTGGCTTGAGTAGATAA		
MyD88	AGCCATTCACACATCTTCACCC	AGCCATTCACACATCTTCACCC GCTATGCTTCACCATTTCCTACA	
TLR6	TGCAGAGTAACAGGAGCACACA ACCCTCGGACTCCAGCAA		
CD14	CTCAGCTGCAACAGACTGAACA	GGAGTTCATTGAGCCCTCGTG	

method. The relative amount of mRNA was determined by subtracting the Ct values for these genes from the Ct value for the housekeeping gene pdhA or 18 s (Δ Ct). The amount of mRNA was expressed relative to the amount of pdhA or 18 s mRNA ($2^{-\Delta\Delta Ct}$) and presented as mean \pm SEM. The sequence of primers is shown in Table 1.

 $\frac{\text{expression levels between the MPP and control groups}}{\text{MPP}(n=66) \quad \text{Control}(n=20) \quad \text{Statistical value} \quad P \text{ value}}$

Table 2 Comparison of CARDS TX and HMGB1 mRNA

	MPP(n=66)	Control(n=20)	Statistical value	P value
CARDSTX	5.33 ± 3.31	0.96 ± 0.20	t = 10.664	0.001
HMGB1	15.50 ± 7.89	1.28 ± 0.55	t = 14.527	0.001

Detection of tumor necrosis factor- $\!\alpha$ and interleukin-1 $\!\beta$ levels by ELISA

The cytokines tumor necrosis factor (TNF)- α and interleukin (IL)-1 β in BALF were detected by the ELISA method. The specific steps were carried out according to the manufacturer's instructions in a commercial ELISA kit (Neobioscience, Shenzhen, China).


Statistical analysis

Data were analyzed with SPSS version 24.0 for Windows (IBM Corp., Armonk, NY, USA). Measurement data that had a normal distribution and homogeneity of variance are expressed as mean \pm SD. The t-test is used for comparison between the two groups. Pearson correlation was used for correlation analysis. Categorical data were analyzed by the chi-square test. A *P* value < 0.05 was considered statistically significant.

Results

CARDS TX and HMGB1 mRNA expression levels and their correlation

Mean CARDS TX and HMGB1 mRNA expression in the MPP group was significantly higher than that in the control group (both P < 0.05, Table 2). There was a positive correlation between HMGB1 and CARDS TX mRNA expression in the MPP group (r = 0.376, P < 0.05, Fig. 1).



Comparison of TNF- α and IL-1 β levels between the MPP and control groups

MPP tends to occur in school-age and preschool children, while bronchial foreign body tends to occur in infants and young children. In order to avoid the influence of age, a total of 20 children with MPP and 10 with foreign bodies (controls) aged 4–7 years were selected for further comparison. Mean TNF- α and IL-1 β levels in the MPP group were significantly lower than those in the control group (all P<0.05, Table 3).

Fan et al. Italian Journal of Pediatrics (2022) 48:64 Page 4 of 6

Table 3 Comparison of TNF- α and IL-1 β levels between the MPP and control groups

	MPP(n = 20)	Control(n = 10)	t value	P value
TNF-α(pg/ml)	23.60 ± 0.44	42.85 ± 10.02	-6.074	0.001
IL-1β(pg/ml)	9.94 ± 0.37	19.53 ± 1.60	-18.756	0.001

Comparison of TLR2, TLR4, RAGE, MyD88, TLR6, and CD14 mRNA expression levels between the MPP and control groups

Mean TLR2, MyD88, and CD14 mRNA levels in BALF in the MPP group were significantly higher than those in the control group (all P < 0.05, Table 4). However, there were no significant differences in the relative expression of TLR4, RAGE, and TLR6 between the two groups.

Correlations of CARDS TX and HMGB1 with TLR2, MyD88, and CD14 in the MPP group

In the MPP group, CARDS TX mRNA expression in BALF was positively correlated with TLR2, MyD88, and CD14 mRNA expression (r=0.665, 0.483, and 0.639, respectively; all P<0.05). HMGB1 mRNA expression was also positively correlated with TLR2, MyD88, and CD14 mRNA expression (r=0.723, 0.668, and 0.707, respectively; all P<0.05, Table 5).

Discussion

In recent years, reports of MPP and RMPP have gradually increased, including reports on how these conditions threaten the lives of children [2, 8]. However, the specific mechanism of RMPP remains unclear. At present, this mechanism is believed to be related to MP drug resistance, immune dysfunction, mixed infection, excessive MP load, mucus suppository, and CARDS TX [9].

CARDS TX is an important toxin produced by MP 3. Some studies that exposed primates to MP and CARDS TX showed similar histopathological changes in the lungs [10]. HMGB1 is an important marker of inflammation.

Table 4 Comparison of TLR2, TLR4, RAGE, MyD88, TLR6, and CD14 mRNA expression levels between the MPP and control groups

	MPP(n = 20)	Control(n=10)	t value	P value
TLR2	12.02 ± 5.60	1.03 ± 0.24	8.755	0.001
TLR4	1.25 ± 0.54	1.01 ± 0.26	1.675	0.105
RAGE	1.12 ± 0.48	0.94 ± 0.23	1.105	0.278
MyD88	20.04 ± 8.80	0.98 ± 0.34	9.675	0.001
TLR6	0.98 ± 0.39	1.01 ± 0.21	-0.248	0.806
CD14	3.09 ± 1.46	0.96 ± 0.28	4.530	0.001

Table 5 Correlations of CARDS TX and HMGB1 mRNA expression with TLR2, MyD88, and CD14 mRNA expression in the MPP group

	CARDS TX		HMGB1	
	r value	P value	r value	P value
TLR2	0.665	0.001	0.723	0.001
MyD88	0.483	0.031	0.668	0.001
CD14	0.639	0.002	0.707	0.001

HMGB1 participates in the immune process in occurrence and development of MPP and is related to the severity of MPP [4, 11]. We studied children with the diagnosis of MPP who were examined by bronchoscopy and bronchoalveolar lavage. We found that CARDS TX and HMGB1 mRNA expression in BALF in the MPP group was significantly higher than that in the control group. This finding is consistent with a study by Ding et al. [4] and Li et al. [11]. There is a positive correlation between HMGB1 and CARDS TX, suggesting that MP may mediate cell injury and stimulate release of HMGB1 through CARDS TX, which may lead to pulmonary inflammation.

TNF- α is the earliest inflammatory factor that is secreted under stimulation of various inflammatory factors, and it is mainly produced by monocytes and macrophages. TNF-α can activate production of secondary inflammatory mediators, such as IL-1\beta, which in turn promotes signal transmission of T cells to initiate the inflammatory response. Studies have shown that MP and CARDS TX stimulate production of pro-inflammatory cytokines, such as TNF- α and IL-1 β [11, 12]. TNF- α and IL-1β can also stimulate mononuclear macrophages to actively secrete HMGB1 to the extracellular environment to play a pro-inflammatory role [13]. However, our study showed that TNF- α and IL-1 β levels in BALF in the MPP group were significantly lower than those in the control group. This finding may be because TNF- α and IL-1 β are early inflammatory factors. The course of disease in the MPP group was longer, and foreign body stimulation in the control group could also have caused production of inflammatory cytokines. Most of the children with foreign bodies were examined by bronchoscopy immediately after foreign bodies were ingested. This further indicated that HMGB1 was a late inflammatory factor.

The typical receptors of HMGB1 are RAGE, TLR2, and TLR4 [14]. TLRs (except for TLR3) can activate the MyD88-dependent pathway and mediate an active inflammatory response [15]. A study on intranasal inoculation of MP in mice showed that macrophages recognized the specific antigen of MP through its surface TLR [16]. This then activated the MyD88-nuclear factor-κB signal pathway, and then cleared the invaded MP from

Fan et al. Italian Journal of Pediatrics (2022) 48:64 Page 5 of 6

the lungs. A decrease in TLR and MyD88 destroys the ability of macrophages to clear MP, indicating that the TLR-MyD88-nuclear factor-kB signaling pathway is important in the process of macrophages clearing MP in the lungs. Our study also showed that relative expression of TLR2 and MyD88 in BALF of children in the MPP group was significantly higher than that in the control group. Additionally, TLR2 and MyD88 mRNA expression was positively correlated with CARDS TX and HMGB1 mRNA expression. However, there were no significant differences in TLR4 and RAGE mRNA expression between the two groups. These findings suggest that the combination of TLR2 and HMGB1 after MP infection plays a role through the MyD88 pathway and participates in the pathogenesis of MP.

TLR6 is also a member of the TLR family. TLR6 is highly homologous to TLR2 in structure and participates in ligand recognition by forming heterodimers with TLR2 [17]. CD14 is also a co-receptor of many types of TLR. As a co-receptor of TLR2, CD14 can improve the sensitivity to external pathogens and promote binding with ligands [18, 19]. He et al. [20] showed that lipid-associated membrane proteins of Mycoplasma genitalium activated nuclear factor-κB in the MyD88-dependent pathway through TLR1, TLR2, TLR6, and CD14. Our study showed that relative expression of CD14 in BALF in the MPP group was significantly higher than that in the control group. Additionally, CD14 mRNA expression was positively correlated with CARDS TX and HMGB1 mRNA expression. However, relative expression of TLR6 in the MMP group was not different from that in the control group. These findings suggest that CD14, as a co-receptor of TLR2, participates in the pathogenesis of MPP.

Conclusions

In summary, after MP infection, CARDS TX stimulates the release of HMGB1, which depends on the TLR2/CD14/MyD88 pathway to activate various downstream signal pathways. This results in inflammatory and immune responses. However, there are some limitations to this study. The sample size of this study was small, and the cytokines studied were limited. Clinical samples are easily affected by age, immune function, and other individual differences, as well as by treatment and other aspects. In future studies, a larger sample size and basic experimental research are required to investigate the immune pathogenesis of MP infection, especially refractory mycoplasma infection.

Abbreviations

BALF: Bronchoalveolar lavage fluid; CARDS TX: Community-acquired respiratory distress syndrome toxin; CD14: Cluster of differentiation 14; HMGB1:

High-mobility group box protein 1; IL-1β: Interleukin-1β; MPP: Mycoplasma pneumoniae Pneumonia; MyD88: Myeloid differentiation factor 88; PCR: Polymerase chain reaction; RAGE: Receptor for advanced glycation end products; TLR: Toll-like receptor; TNF-α: Tumor necrosis factor-α.

Acknowledgements

We thank Ellen Knapp, PhD, from Liwen Bianji, Edanz Group China (www.liwen bianji.cn/ac), for editing the English text of a draft of this manuscript.

Authors' contributions

YF and YD carried out the molecular genetic studies, participated in sequence alignment, and drafted the manuscript. YL, DZ and MY collected and analyzed clinical data, and participated in sequence alignment. WZ and XK designed the experiment and drafted the manuscript. All authors read and approved the final manuscript.

Funding

The study was supported by the Scientific and Technological Project for Community Development of Suzhou (No. SS201535).

Availability of data and materials

All data are available.

Declarations

Ethics approval and consent to participate

This study was conducted with the approval of the Institutional Human Ethical Committee of the Children's Hospital of Soochow University. IAn informed consent was obtained from all of the subjects or guardians who participated in this study.

Consent for publication

All authors have read and approved the content, and they agree to submit it for consideration for publication in the journal.

Competing interests

The authors declare that they have no competing interests.

Received: 4 July 2020 Accepted: 8 April 2022 Published online: 03 May 2022

References

- Atkinson TP, Waites KB. Mycoplasma pneumoniae Infections in Childhood[J]. Pediatr Infect Dis J. 2014;33(1):92–4.
- Gao LW, Yin J, Hu YH, et al. The epidemiology of paediatric Mycoplasma pneumoniae pneumonia in North China: 2006 to 2016[J]. EPIDEMIOL-OGY AND INFECTION. 2019;147:e192.
- Kannan TR, Baseman JB. ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens[J]. Proc Natl Acad Sci U S A. 2006;103(17):6724–9.
- Ding Y, Chu C, Li Y, et al. High expression of HMGB1 in children with refractory Mycoplasma pneumoniae pneumonia[J]. BMC Infect Dis. 2018;18(1):439.
- National Health Commission of the People's Republic of China, National Administration of Traditional Chinese Medicine. Guideline for diagnosis and treatment of community-acquired pneumonia in Children (2019 version)[J]. Chin J Clin Infect Dis. 2019;12(1):6–13.
- Experts Group of Pediatric Respiratory Endoscopy, Talent Exchange Service Centerof National Health Commissio, Endoscopy Committee, et al. Guideline of pediatric flexible bronchoscopy in China (2018 version)[J]. Chin J Appl Clin Pediatr. 2018;33(13):983–9.
- 7. Yan Y, Wei Y, Jiang W, Hao C. The clinical characteristics of corticosteroid-resistant refractory Mycoplasma pneumoniae pneumonia in children[J]. Sci Rep. 2016;6:39929.
- Park SJ, Pai KS, Kim AR, et al. Fulminant and Fatal Multiple Organ Failure in a 12-Year-Old Boy With Mycoplasma pneumoniae Infection[J]. Allergy Asthma Immunol Res. 2012;4(1):55–7.

- 9. Zhang Q. Mechanism and Treatment of Refractory Mycoplasma Pneumoniae Pneumonia in Children [J]. J Pediatr Pharm. 2019;25(6):61–3.
- Maselli DJ, Medina JL, Brooks EG, et al. The immunopathologic effects of mycoplasma pneumoniae and community-acquired respiratory distress syndrome toxin. a primate model[J]. Am J Respir Cell Mol Biol. 2018;58(2):253–60.
- Li G, Fan L, Wang Y, et al. High co-expression of TNF-alpha and CARDS toxin is a good predictor for refractory Mycoplasma pneumoniae pneumonia[J]. Mol Med. 2019;25(1):38.
- Shimizu T, Kida Y, Kuwano K. Cytoadherence-dependent induction of inflammatory responses by Mycoplasma pneumoniae[J]. Immunology. 2011;133(1):51–61.
- 13. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes[J]. J Exp Med. 2000;192(4):565–70.
- 14. Kang R, Chen R, Zhang Q, et al. HMGB1 in health and disease[J]. Mol Aspects Med. 2014;40:1–116.
- Afkham A, Eghbal-Fard S, Heydarlou H, et al. Toll-like receptors signaling network in pre-eclampsia: An updated review[J]. J Cell Physiol. 2019;234(3):2229–40.
- Lai JF, Zindl CL, Duffy LB, et al. Critical role of macrophages and their activation via MyD88-NFkappaB signaling in lung innate immunity to Mycoplasma pneumoniae[J]. PLoS One. 2010;5(12):e14417.
- Takeda K, Takeuchi O, Akira S. Recognition of lipopeptides by Toll-like receptors[J]. J Endotoxin Res. 2002;8(6):459–63.
- Manukyan M, Triantafilou K, Triantafilou M, et al. Binding of lipopeptide to CD14 induces physical proximity of CD14, TLR2 and TLR1[J]. Eur J Immunol. 2005;35(3):911–21.
- Nakata T, Yasuda M, Fujita M, et al. CD14 directly binds to triacylated lipopeptides and facilitates recognition of the lipopeptides by the receptor complex of Toll-like receptors 2 and 1 without binding to the complex[J]. Cell Microbiol. 2006;8(12):1899–909.
- He J, You X, Zeng Y, et al. Mycoplasma genitalium-derived lipid-associated membrane proteins activate NF-kappaB through toll-like receptors 1, 2, and 6 and CD14 in a MyD88-dependent pathway[J]. Clin Vaccine Immunol. 2009;16(12):1750–7.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- $\bullet\,$ thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

